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tions. Seven state Markov model (chronic HCV, sustained virological response,
compensated cirrhosis, hepatocellulare carcinoma, liver transplantation and
death) was used to estimate clinical effects and costs in lifetime horizon, from
Polish public payer perspective. Direct medical costs were considered. Separate
analysis was done for genotypes 1,4 (48-week treatment) and genotypes 2,3 (24-
week treatment). Clinical practice and cost data were gathered from clinical ex-
perts or based on the National Health Fund and Ministry of Health published price
lists. Sensitivity analysis was conducted in order to assess the robustness of the
results. RESULTS: Genotypes 1 and 4: total costs were 92 036 PLN (1 Euro3.96 PLN)
for PegIFN2a and 87 793 PLN for PegIFN2b. Average survival of HCV patient
treated with PegIFN2a was 27.9 life years (LY) and 14.83 quality adjusted life years
(QALY) and treated with PegIFN2b was 27.63 LYs and 14.61 QALYs. The incremen-
tal cost-effectiveness ratio was 15 878 PLN/LYG and incremental cost-utility ratio
was 19 763 PLN/QALY. Values of both ratios fall below the cost-effectiveness
threshold assumed in Poland (100 000 PLN/LYG or QALY). Genotypes 2 and 3: Total
costs were 32 849 PLN for PegIFN2a and 38 071 PLN for PegIFN2b. Average survival
of HCV patient treated with PegIFN2a was 30.79 LYs and 17.15 QALYs and treated
with PegIFN2b was 30.20 LYs and 16.68 QALYs. The PegIFN2a dominated
PegIFN2b. The results were confirmed in sensitivity analysis. CONCLUSIONS:
PegIFN2a is a clinically effective and safe treatment for HCV patients and is highly
cost-effective (or dominant) from Polish public payer perspective.
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OBJECTIVES: Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-
valent pneumococcal conjugate vaccine (PCV10) are two approved vaccines for the
active immunization against Streptococcus pneumoniae, causing invasive pneumo-
coccal disease in infants and children. PCV13 offers broader protection against
Streptococcus pneumoniae; however, PCV10 offers potential additional protection
against non-typeable Haemophilus influenzae. We examined public health and eco-
nomic impacts of a PCV10 and PCV13 pediatric national immunization programs
(NIPs) in Canada.METHODS: A decision-analytic model was developed to examine
the costs and outcomes associated with a 21 dosing of PCV10 and 21 dosing of
PCV13 pediatric NIP. The model followed patients over the remainder of their life-
time. Recent disease incidence, serotype coverage, population data, percent vacci-
nated, costs, and utilities were obtained from the published literature. Direct and
indirect effects were derived from 7-valent pneumococcal vaccine. Additional di-
rect effect of 4% was attributed to PCV10 for moderate to severe AOM to account for
potential non-typeable Haemophilus influenzae benefit. Annual number of disease
cases and costs (2010 CAN$) were presented. RESULTS: In Canada, PCV13 pre-
vented more cases of disease (7,465 when considering direct effects only and 49,340
when considering both direct and indirect effects) than PCV10. This translated to
population gains of 80,565 to 94,134 more quality-adjusted life years when vacci-
nating with PCV13 versus PCV10. Use of PCV13 in children also reduced annual
direct medical costs (including the cost of vaccination) by $5.8 to $132.8 million.
Thus, PCV13 was found to dominate PCV10. One-way sensitivity analyses showed
PCV13 to always be dominant or cost-effective versus PCV10. CONCLUSIONS: Con-
sidering the epidemiology of pneumococcal disease in Canada, 21 dosing of
PCV13 is shown to be a cost saving immunization program as it provides substan-
tial public health and economic benefits relative to 21 dosing of PCV10.
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OBJECTIVES: The analysis aimed to evaluate the cost-effectiveness of 48-week
therapy with peginterferon alpha-2a (PegIFN-2a) in HBeAg-positive chronic hep-
atitis B (CHB) patients versus 48-week (short-term analysis) or 4-year (long-term
analysis) therapy with adefovir, entecavir or lamivudine from the public payer
perspective in Poland. METHODS: A life-time Markov model based on previously
published analysis was used. States encompassed treatment response (HBeAg se-
roconversion), relapse, complications (compensated/decompensated cirrhosis,
hepatocellular carcinoma, liver transplantation) and death. Quality-adjusted life
years (QALYs) were the measure of effectiveness. Short-term efficacy assessment
was based on the results of randomized clinical trials (RCTs). Long-term efficacy
data for nucleos(t)ide analogues (NAs) were derived from published models and
RCTs extensions. Utilities and transition probabilities (spontaneous response, re-
lapse, complications, death) were taken from published literature. Direct medical
costs, i.e. costs of drugs and procedures used in the treatment of CHB and its
complications were obtained using a survey conducted among Polish clinicians. In
the base case analysis costs and benefits were discounted at a 5% and 3.5% annual
rate, respectively. The robustness of the results was assessed using one-way, sce-
nario and probabilistic sensitivity analyses. RESULTS: In both the short and long-
term analysis PegIFN-2a increased number of QALYs and life years gained (LYGs)
compared to all investigated NAs. In the short-term model PegIFN-2a decreased
the costs of complications’ treatment and increased the overall costs due to drug
acquisition cost. ICER for PegIFN-2a vs. lamivudine, adefovir and entecavir
amounted to 50,809, 11,442 and 39,588 PLN/QALY, respectively (1€4 PLN). In the
long-term model costs of NAs were higher. PegIFN-2a was cost-saving and dom-
inated adefovir and entecavir, while ICER versus lamivudine amounted to 27,431
PLN/QALY. Sensitivity analysis proved these results to be robust. CONCLUSIONS:
Peginterferon alfa-2a is cost-effective when compared to adefovir, entecavir and
lamivudine in Poland.
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OBJECTIVES: IMPACT trial showed that prolonged prophylaxis of 200 days with
valganciclovir (VGC 200) compared with 100 days (VGC 100) significantly decreases
the incidence of cytomegalovirus (CMV) disease. Therefore, a cost-effectiveness
model was developed to evaluate prolonged prophylaxis of 200 days with valgan-
ciclovir and its long term economic impact . METHODS: A Markov model was
designed to simulate the CMV disease progression; costs and outcomes associated
with the use of VGC 200 vs VGC 100 in a cohort of 10,000 patients over 10 years was
examined. Data of the disease evolution were obtained from the IMPACT (Humar,
Am J Transplant 2010) for year 1 and the available scientific evidence for years 2-10.
The analysis was conducted from the perspective of the Spanish National Health-
care System (SNHS), considering direct medical costs. Unitary costs (€, 2010) were
obtained from a Spanish database. Utility values were obtained from literature. The
annual discount rate was 3% for costs and outcomes. RESULTS: Treatment with
VGC 200 provides better results in health than VGC 100 (50,020.30 vs. 47,639.90
QALY/patient). The average overall cost per patient is €1,121,327 with VGC 200 and
€1,131,187 with VGC 100. The savings per patient treated with VGC 200 in 10 years
is €986. Sensitivity analysis confirms the stability of the results. CONCLUSIONS:
Treatment of patients with prolonged prophylaxis valganciclovir reduces the inci-
dence in high risk kidney transplant recipients and is a cost-saving strategy in CMV
disease management from the perspective of the SNHS.
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OBJECTIVES: In Uganda, 91,000 children are born annually to HIV-positive moth-
ers, approximately 25,000 of which become HIV-infected. New guidelines recom-
mend the use of combination antiretroviral therapy (cART) to prevent vertical
transmission. We evaluate the cost-effectiveness of more costly cART relative to
other or no preventative therapies. METHODS: Currently, about 48.4% of HIV-pos-
itive pregnant women do not receive any preventive therapies and therefore have
a 40% risk of transmitting HIV to their child during pregnancy or breastfeeding.
This risk can be reduced to 25.8% by single dose nevirapine (sdNVP; Cost: US$0.06),
to 17.4% by dual therapy (3TC/AZT; Cost: US$16 for 7 weeks) and to 3.8% by cART
(Cost: US$470 for 18 months). At CD4 counts below 350 cells/l, lifetime cART is
indicated for the mother (Cost: US$ 6,883), which reduces future transmission risk
in an additional 3.49 pregnancies. The model calculates disability adjusted life
years (DALY’s) between therapies based on differences in HIV-transmission to chil-
dren, which results in shortened life-expectancy. All costs and benefits are dis-
counted at 3% annually. RESULTS: Replacing sdNVP and 3TC/AZT with cART could
reduce annual HIV transmissions by 7,500 cases. Preventing one infection averts
23.7 DALY’s. Hence, DALY’s averted using 18 months cART versus sdNVP, 3TC/AZT,
and no therapies are 5.21, 3.22, and 8.58, and yield a cost/DALY averted of US$46,
US$99, and US$34, respectively. The corresponding figures for lifetime cART are
19.20, 11.87, and 31.60, resulting in a cost/DALY averted of US$205, US$354 and
US$172, respectively. CONCLUSIONS: Using the 1 time per capita GDP threshold
(US$460), cART as proposed in the new Ugandan guidelines is highly cost-effective
relative to other drugs and would generate additional value if treatment could
reach greater numbers of women. It remains highly cost-effective even if treatment
is continued over the patients’ lifetimes. It is imperative that these guidelines are
rapidly implemented.
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OBJECTIVES: It is estimated that pneumococcal disease is responsible for more
than a million deaths per year in children less than five years of age worldwide.
This study aim to perform a cost-effectiveness analysis comparing pneumococcal
13-valent conjugate vaccine (PCV13) against pneumococcal 10-valent conjugate
vaccine in prevention of invasive pneumococcal diseases (IPD), acute otitis media
(AOM) and pneumonia, from the São Paulo Public Healthcare System perspective.
METHODS: The type of study was cost-effectiveness analysis based on a decision
tree model to estimate costs and consequences of prophylaxis. Epidemiological
and efficacy data was collected from a critical appraisal of the scientific literature,
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public databases information and clinical expert panel. The target population was
a birth cohort in São Paulo followed for 5 years (598,474). The vaccination coverage
rate was 90%, considering a four-dose schedule for 10-valent and tree-dose sched-
ule for PCV13 as suggested by international guides. São Paulo costs and disease
data was obtained from national official databases. A mandatory discounted price
to the government, calculated by the ex-factory price minus 24.38% was considered
to PCV13 and 10-valent. Costs and benefits were discounted at 5% annually. Out-
comes were expressed as life years gained(LYG), deaths and number of disease
cases avoided. Only the direct effect of vaccination and direct medical costs were
considered. RESULTS: The analysis showed higher clinical benefits and lower
costs for PCV13 prophylaxis; reduction of 7 deaths, 488 LYG and 17 cases of
disease (sepsis and meningitis) and savings of BRL70,097,844(USD43,909,950) in
5 years. The total costs with events and vaccines were
BRL113,902,160(USD72,576,883) and BRL137,914,893(USD87,877,465), respec-
tively, for PCV13; and BRL113,999,789(USD71,410,542) and
BRL207,915,109(USD130,239,983) for 10-valent. CONCLUSIONS: This study dem-
onstrated that incorporating PCV13 in pediatric immunization routine results in
reduction on mortality and morbidity with lower expected cost for São Paulo state
healthcare system, showing the dominance of PCV13 regarding 10-valent.
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OBJECTIVES: Invasive aspergilosis (IA) is a mycotic disease produce by Aspergillus
sp and represents the second leading cause of invasive fungal infections. The mor-
tality rate is about 50%. The aim of this study was to assess the cost-effectiveness
(CE) of voriconazol, anfotericine B and caspofungin as first line treatments for IA
adult patients in Panama, from the healthcare payer’s perspective. METHODS: A
decision-tree model was used to compare costs and effectiveness of anfotericine B
(comparator), caspofungin and voriconazol for a cohort of patients with IA. Effec-
tiveness measures were: clinical success rates, mortality rates, intensive care unit
(ICU) length of stay (LOS), hospital ward LOS and overall costs. Effectiveness and
epidemiologic data were collected from published literature. Local costs (2011 US$)
were obtained from Panama=s Social Security and Hospital Oncológico Nacional
official databases. The model used a 12-week time horizon and only direct medical
costs were considered. Monte Carlo probabilistic sensitivity analysis (PSA) was
constructed. RESULTS: Results showed voriconazol as the most effective and least
expensive option for IA. Clinical success rate was higher with voriconazol (56.6%)
compared with anfotericine B (36.4%) and caspofungin (34.2%). Mortality rates
were: 34.1% with voriconazol, 50.9% with anfotericine B and 44.7% with caspofun-
gin. Average ICU LOSs was 7.59 days with voriconazol and 9.94 and 9.81 days with
anfotericine B and caspofungin, respectively. Voriconazol also obtained the short-
est ward LOS (15.96 days). Overall medical costs were $13,100 with voriconazol,
$17,347 with anfotericine B and $13,716 with caspofungin. CE analyses showed
voriconazol as the dominant strategy. Acceptability curves showed that voricona-
zol would be cost-effective within 3 GDP per capita threshold. PSA outcomes
support the robustness of these findings. CONCLUSIONS: This is the first CE study
for IA developed in Panamá. Voriconazol resulted as the cost-saving option for
treating IA patients in the Panamanian clinical context.
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OBJECTIVES: The aim of this study is to analyze the cost-effectiveness over 6-year
duration of first line telbivudine and lamivudine treatment in HBeAg-positive
chronic hepatitis B patients with low viral load at baseline in line with the Turkish
reimbursement guideline for oral CHB therapies. METHODS: Using a decision an-
alytical model, cost-effectiveness of telbivudine was evaluated versus lamivudine
in first-line use for HBeAg-positive patients with baseline HBV DNA levels9 log10
copies/mL in Turkish healthcare setting from National Payer’s perspective in ac-
cordance with the local reimbursement guideline for oral CHB treatments based on
roadmap concept. Primary measure of effectiveness was undetectable HBV DNA
level by polymerase chain reaction (PCR) assay at model duration, while costs
included only cost of oral CHB drugs incurred by the Payer. Probabilities of PCR
negativity and resistance rates used in the model are derived from telbivudine’s
head-to-head study versus lamivudine subgroup analyses outcomes for week 24
and 104; and from respective pivotal clinical studies for second line treatments.
RESULTS: In the CE model, total oral CHB treatment cost per HBeAg-positive pa-
tient treated with lamivudine and telbivudine arm over 6 years was estimated to be
12,873€ and 11,435€ respectively. Percentage of patients remaining on lamivudine
at model duration was 23%, while 50% on telbivudine. The average cost-effective-
ness ratio, cost per successfully treated HBeAg-positive patient at year 6, was cal-
culated as 15,362€ for the lamivudine arm and 13,053€ for the telbivudine arm
(difference is 2,309€), and the incremental cost-effectiveness ratio was -37,859€.
CONCLUSIONS: First line CHB treatment with telbivudine in HBeAg-positive pa-
tients has been demonstrated as a dominant cost-effective option than lamivudine
in the Turkish healthcare setting. Although telbivudine has higher reimbursement
price, it has been offset by superior efficacy compared to lamivudine in positive
patients with baseline serum HBV DNA levels9 log10 copies/mL and less need for
more costly second line treatments.
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OBJECTIVES: To estimate the cost of virologic response at week 48 of treatment
with etravirine (ETV), raltegravir (RAL) and maraviroc (MAV) for multi-experienced
patients with 2 or more active drugs in the optimized background therapy (OBT) in
the Brazilian National AIDS Program. METHODS: Treatment regimens of ETV and
RAL were defined by the Brazilian national guidelines. Regimens with MAV were
based in the same principles, although the drug is not yet reimbursed. Patients not
achieving virologic response followed onto subsequent rescue treatments, defined
by the guidelines. Re-treatment was not allowed. Treatment costs included cost of
medication as published on the government website. The cost of MAV was defined
by law. The number of multi-experienced patients receiving treatment was based
on the dispensed capsules of RAL in the last 48 weeks. Virologic response was
gathered from the phase III clinical trials of ETV, MAR and RAL, at week 48 for
patients with two active drugs in the OBT defined by phenotypic susceptibility.
RESULTS: The average cost of treatment at week 48 for multi-experienced patients
with at least 2 active drugs in the OBT was R$ 27,243.14 with ETV, compared with R$
27,702.91 with RAL, and R$ 31,220.72 with MAR. Given 5,627 multi-experienced
patients received treatment, 862 patients failed with MAV, 544 failed treatment
with RAL compared to 337 failed patients with ETV. For one third of the cohort
(1.875), the total cost of treatment was R$ 58,565,276 for MAV, R$ 51,966,391 for RAL,
and R$ 51,103,946 for ETV. CONCLUSIONS: Despite similar treatment costs, treat-
ment with ETV compared to RAL and MAV is a more economic option for the
treatment of multi-experienced patients with at least two active drugs in the OBT.
At week 48, treatment with RAL and MAV was on average 2% and 15% more expen-
sive compared to ETV, respectively.
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OBJECTIVES: To develop a cost-effectiveness analysis of a multidisciplinary sup-
port program (MSP) versus the conventional approach in the Hepatitis C (HC)
treatment. METHODS: A total of 278 mono-infected naive HC patients were in-
cluded: 131 in the MSP group and 147 patients were conventionally controlled
(control group). All patients were treated with Peg-IFN-alfa-2a/ribavirin. The MSP
team not only included hepatologists and nurses, but also, pharmacists, psychol-
ogists and assistants. Standard patient education, open and flexible visits sched-
uling, continued psychiatric evaluation and active medication control were carried
out in the MSP. Treatment adherence, sustained virological response (SVR), and
health resources use were evaluated. A Markov model for a lifetime horizon with
seven health states and from the Spanish NHS perspective was developed. Tran-
sition probabilities and health states utilities were obtained from published liter-
ature. Costs were obtained from the Catalogue of Medicinal Products and from
Spanish studies and databases (€-2010). 3.5% annual discount for costs and out-
comes was applied. RESULTS: In the MSP group treatment compliance was higher
than in the control group (94.6% vs 78.9%, p0.0001). SVR was higher in the MSP
group than in controls for all genotypes (77.1% vs. 61.9%, p0.006), G-1/4 (67.7% vs
48.9%, p0.02), and G-2/3 (87.7% vs. 81.4%, NS). For all genotypes, the cost per
patient (including cost of drugs, health professionals and disease long-term com-
plications) was €13,319 in MSP group and €16,184 in control group, furthermore,
MSP group resulted more QALYs than controls (16.317 vs. 15.814), being MSP dom-
inant (more effective, with lower costs) compared with the conventional approach.
The MSP program was also dominant in G-1/4 patients (saving €2476, increasing
0.622 QALYs/patient) and G-2/3 (saving €1417, gaining 0.208 QALYs/patient). Re-
sults were stable for 95% CI of drug doses. CONCLUSIONS: HC treatment with
Peg-IFN-alfa-2a/ribavirin in a MSP improves the compliance and is a cost-effective
strategy compared with the conventional approach.
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OBJECTIVES: In 2010, there were more than 1500 illness related to Streptococcus
pneumonia infections in pediatric population under 2 years old in Panamá. Cur-
rently, in Panamá, Prevenar 7 is the anti-pneumococcal vaccine (PCV) used. The
aim of this study was to estimate the cost-effectiveness and cost-utility of immu-
nization strategies based on pneumococcal conjugated vaccines (PCVs) in Panamá,
from an institutional perspective. METHODS: A decision tree steady state model
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